OSR (NASDAQ:OSRH) Issues Earnings Results

OSR (NASDAQ:OSRH – Get Free Report) released its earnings results on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, Zacks reports. OSR had a negative net margin of 619.82% and a negative return on equity of 13.53%.

OSR Stock Performance

OSR stock traded down $0.03 during trading on Wednesday, hitting $0.62. The company’s stock had a trading volume of 1,996,083 shares, compared to its average volume of 17,752,332. The stock’s fifty day moving average is $0.53 and its 200 day moving average is $0.58. OSR has a 1-year low of $0.38 and a 1-year high of $1.79. The stock has a market capitalization of $21.64 million, a price-to-earnings ratio of -0.48 and a beta of 0.86.

Get OSR alerts:

Institutional Trading of OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP acquired a new stake in shares of OSR Holdings, Inc. (NASDAQ:OSRH – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned about 0.37% of OSR at the end of the most recent reporting period. Institutional investors and hedge funds own 55.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of OSR from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

View Our Latest Research Report on OSRH

About OSR

(Get Free Report)

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.

Featured Stories

• Five stocks we like better than OSR
• D-Wave Earnings Looked Weak, But Investors May Be Missing This
• Nebius Upside Expands as AI Feedback Loop Intensifies
• Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
• Plug Power Flips The Switch On Profitability

Receive News & Ratings for OSR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OSR and related companies with MarketBeat.com's FREE daily email newsletter.